Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Change in Accured Expenses (2020 - 2023)

Historic Change in Accured Expenses for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to $946000.0.

  • Candel Therapeutics' Change in Accured Expenses rose 11747.13% to $946000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was -$301000.0, marking a year-over-year decrease of 12379.45%. This contributed to the annual value of $757000.0 for FY2024, which is 35149.5% up from last year.
  • According to the latest figures from Q4 2023, Candel Therapeutics' Change in Accured Expenses is $946000.0, which was up 11747.13% from -$85000.0 recorded in Q3 2023.
  • Candel Therapeutics' Change in Accured Expenses' 5-year high stood at $1.4 million during Q4 2020, with a 5-year trough of -$1.8 million in Q1 2023.
  • In the last 4 years, Candel Therapeutics' Change in Accured Expenses had a median value of $310500.0 in 2022 and averaged $198714.3.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 51060.61% in 2021, then plummeted by 208888.89% in 2023.
  • Over the past 4 years, Candel Therapeutics' Change in Accured Expenses (Quarter) stood at $1.4 million in 2020, then tumbled by 48.24% to $719000.0 in 2021, then plummeted by 39.5% to $435000.0 in 2022, then skyrocketed by 117.47% to $946000.0 in 2023.
  • Its Change in Accured Expenses was $946000.0 in Q4 2023, compared to -$85000.0 in Q3 2023 and $628000.0 in Q2 2023.